Mark Foley, Revance CEO (Revance via Vimeo)

FDA re­jects Re­vance's pitch for Botox com­peti­tor as biotech blames man­u­fac­tur­ing is­sues

The FDA has told Re­vance Ther­a­peu­tics that, no, it won’t be able to turn those frowns up­side down.

Reg­u­la­tors is­sued a CRL to the biotech …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.